Bill shifts drug oversight to health director
The new centre would represent the city abroad and court leading overseas regulators.
Hong Kong has published a bill seeking to establish the Centre for Medical Products Regulation (CMPR) as a statutory body and streamline the regulatory framework for Chinese and Western medicines.
The bill proposes establishing the CMPR as a corporate body to represent Hong Kong in international regulatory affairs and build long-term partnerships with leading regulatory authorities worldwide.
It also seeks to consolidate regulatory powers and functions for Chinese and Western medicines, currently held by the Pharmacy and Poisons Board and the Chinese Medicines Board, under the Director of Health.
Similar arrangements for medical devices will follow under future legislation.
Other proposals include strengthening supporting mechanisms and making technical amendments to existing legislation.
Secretary for Health Lo Chung-mau said the government would support the emerging biomedicine industry in developing innovative medical products, facilitating their introduction into Hong Kong and expansion into international markets.
He added that the government would establish a proactive evaluation and approval mechanism to accelerate the introduction of advanced medical products into the city.
The bill will be introduced to the Legislative Council for its first reading on 25 November.